NGL earning presentation Q4 and FY22:
Revenue growth of 17% in Q4 and 23% in FY22.
Margins impacted by rising commodity, freight and fuel. Costs are expected to remain at elevated levels in the near term.
High customer retention, strong demand in key markets.
Robust demand in fy22 in anthelmentics and anti parasites, top 5 products continued to gain market share.
Product portfolio: 22 APIs( 18 vet,4 human),4 intermediates,10 finished dosage forms.
Leadership in top 3 products of vet API(>50% market share), gaining market share in next 4 products.
5 molecules in pipeline having more than 5 step synthesis manufacturing, will lead to new margin accretive products.
90% capacity utilization during fy22(excluding Macrotech expansion). Completed 26cr expansion in Macrotech during the year, approvals are in place and validation batches initiated.
Greenfield capacity expansion at Tarapur at estimated capex of 140cr(debt+internal accruals), undergoing civil construction, expected to commercialize in FY24.
Increased inventories(56Cr vs 38Cr in fy21) due to new products development and change in product mix.
discl: tracking